The head of search and evaluation at the Alzheimer's Drug Discovery Foundation discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]
Aaron Burstein, PharmD
Advertisement
Head of search and evaluation at the Alzheimer's Drug Discovery Foundation.
Articles by Aaron Burstein, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Overviewing Emerging Evidence of Vaccines, Dementia Risk, and Pathogen Protection: Pierre Tariot, MD
2
What the EC Decision on High-Dose Spinraza Means for SMA Care
3
Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits
4
Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time
5